Results 71 to 80 of about 2,024 (91)

ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández, Karen L. Reyes‐Barrera, Sergio N. Hidalgo‐Figueroa, Edgar D. Páez‐Pérez, Clara I. Espitia Pinzón, Ángel G. Alpuche‐Solís   +5 more
wiley   +1 more source

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID‐19 and Oncology (2020–2025)

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 7, July 2026.
ABSTRACT Drug repurposing presents a cost‐effective and time‐efficient strategy to identify new therapeutic applications for existing drugs. Recent advances in artificial intelligence, including machine learning, deep learning, knowledge graphs, and natural language processing, have revolutionized this field by enabling automated discovery of drug ...
Alaba Bukola Ogungbite, Malusi Sibiya
wiley   +1 more source

When serious becomes critical

Journal of Hospital Medicine, EarlyView.
Yohei Masuda
wiley   +1 more source

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants

Clinical and Translational Science
Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID‐19 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive ...
Jack Chang, Aryun Kim, Rita Humeniuk, Naveed A. Shaik, Helen Winter, Chi‐Chi Peng, Deqing Xiao, Mazin Abdelghany, Joe Llewellyn, Santosh Davies, Kandace Golden, Shuguang Chen, Robert H. Hyland, Luzelena Caro   +13 more
doaj   +1 more source

Assessing the effect of remdesivir alone and in combination with corticosteroids on time to death in COVID-19: A propensity score-matched analysis

Journal of Clinical Virology Plus
Background: This study aimed to evaluate the impact of remdesivir, alone or in combination with corticosteroids, on the time to death in COVID-19 patients. Methods: This retrospective cohort study was conducted between March 20, 2020, and March 18, 2021,
Mohamad Amin Pourhoseingholi, Mehdi Azizmohammad Looha, Saba Ilkhani, Hamidreza Hatamabadi, Amir Sadeghi, Seyed Amir Ahmad Safavi-Naini, Kamran Heidari, Nazanin Taraghikhah, Mohammad Mahdi Fallah, Reyhaneh Kalantar, Nariman Naderi, Romina Esbati, Nastaran Ebrahimi, Ali Solhpour, Tannaz Jamialahmadi, Amirhossein Sahebkar   +15 more
doaj   +1 more source

Remdesivir inhibits endothelial activation and atherosclerosis by coupling TAL1 to TRAF6

Journal of Translational Medicine
Background Atherosclerosis is characterized by complex pathological processes, including endothelial dysfunction and inflammation. The underlying pathogenic mechanisms have been well elucidated; however, effective treatments are yet to be validated.
Hanning Zhang, Ruru Li, Qianqian Huo, Li Li, Min Li, Shunxin Hu, Changjie Ren, Zongyin Wu, Chenghu Zhang   +8 more
doaj   +1 more source

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance

Viruses
Various SARS-CoV-2 remdesivir resistance-associated substitutions (RAS) have been reported, but a comprehensive comparison of their resistance levels is lacking.
Carlota Fernandez-Antunez, Line A. Ryberg, Kuan Wang, Long V. Pham, Lotte S. Mikkelsen, Ulrik Fahnøe, Katrine T. Hartmann, Henrik E. Jensen, Kenn Holmbeck, Jens Bukh, Santseharay Ramirez   +10 more
doaj   +1 more source

The impact of remdesivir on SARS-CoV-2 evolution in vivo

JCI Insight
The impact of remdesivir on SARS-CoV-2 diversity and evolution in vivo has remained unclear. In this single-center, retrospective cohort study, we assessed SARS-CoV-2 diversification and diversity over time in a cohort of hospitalized patients who did or
Ted Ling-Hu, Lacy M. Simons, Estefany Rios-Guzman, Alexandre Machado Carvalho, Maria Francesca R. Agnes, Arghavan Alisoltanidehkordi, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist   +8 more
doaj   +1 more source

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load

Scientific Reports
The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load.
Petr Waldauf, Ivana Jurisinova, Eva Svobodova, Michaela Diblickova, Tomas Tencer, Jan Zavora, Gabriela Smela, Lenka Kupidlovska, Vaclava Adamkova, Marta Fridrichova, Karolina Jerabkova, Jakub Mikes, Frantisek Duska, Ladislav Dusek, Martin Balik   +14 more
doaj   +1 more source

Severe myocardium suppression in two congenital heart disease patients after remdesivir use – a case report

BMC Pediatrics
Background Remdesivir, the first FDA-approved antiviral for SARS-CoV-2, has shown clinical benefits in early COVID-19 but is associated with cardiac adverse events.
Yi-Fan Lin, Shih-Yu Fang, Shu-Chien Huang, En-Ting Wu   +3 more
doaj   +1 more source